Oncopeptides AB

Oncopeptides AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company uses its proprietary peptide-drug conjugate (PDC) platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The first drug coming from PDC platform, PEPAXTO®(melphalan flufenamide), has been launched in the U.S., for the treatment of adult patients with relapsed or refractory multiple myeloma. Melphalan flufenamide is evaluated in a comprehensive clinical study program including the global phase 3 studies OCEAN and LIGHTHOUSE. Oncopeptides is developing several new compounds based on the PDC platform. The first one is expected to enter into clinical development in 2021.Oncopeptides has approximately 300 coworkers. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on www.oncopeptides.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Invitation to presentation of the Q1 2021 results

Thu, May 20, 2021 08:30 CET

STOCKHOLM — May 20, 2021 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, will publish its report for the first quarter 2021 on May 26. Investors, financial analysts and media are invited to participate in a webcast with a QnA session on the same day at 12:00 CEST. The event will be hosted by CEO, Marty J Duvall and members of the Oncopeptides’ Leadership team. The presentation will be held in English.The webcast will be streamed via this link

There are no items matching the current filter

There are no more items matching the current filter

Share

About Us

Invitation to presentation of the Q1 2021 results

Subscribe

Media